India, Oct. 20 -- Cipla has announced that it has launched generic Nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF). Available as 100 mg and 150 mg capsules, it will be marketed under the brand name Nintib. This launch marks yet another milestone in Mumbai based company's decade-long commitment to treat IPF, a rare lung disease that impacts ten in one lakh people.

Cipla's journey in IPF began in 2010 with the introduction of Pirfenex, the world's first generic Pirfenidone and the first ever approved drug for IPF in India. Further to this, Cipla reduced the cost of its IPF therapy by 40 per cent in 2013 to provide patient-access to this critical treatment. In line with its endeavour of enabling effective and affordable ...